There is not a large amount of data available to allow clinicians to determine whether patients should remain on or cease venetoclax treatment. In this interview, Constantine Tam, MD, FRACP, FRCPA, of Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the issue. Dr Tam highlights data from a study of chronic lymphocytic leukemia (CLL) patients using a combination of venetoclax and rituximab, in which several patients ceased treatment. He also presents the logical case of treatment cessation in terms of hindering drug resistance. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Cessation of venetoclax and remaining in remission from CLL?
